NKTR
Price
$56.38
Change
-$0.70 (-1.23%)
Updated
Oct 15, 11:16 AM (EDT)
Capitalization
1.09B
Intraday Buy/Sell Signals
SKYE
Price
$1.57
Change
+$0.05 (+3.29%)
Updated
Oct 15, 11:15 AM (EDT)
Capitalization
47.1M
Intraday Buy/Sell Signals
Interact to see
Advertisement

NKTR vs SKYE

Header iconNKTR vs SKYE Comparison
Open Charts NKTR vs SKYEBanner chart's image
Nektar Therapeutics
Price$56.38
Change-$0.70 (-1.23%)
Volume$3.12K
Capitalization1.09B
Skye Bioscience
Price$1.57
Change+$0.05 (+3.29%)
Volume$10.92K
Capitalization47.1M
NKTR vs SKYE Comparison Chart in %
NKTR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NKTR vs. SKYE commentary
Oct 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NKTR is a Hold and SKYE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 17, 2025
Stock price -- (NKTR: $57.06 vs. SKYE: $1.52)
Brand notoriety: NKTR: Notable vs. SKYE: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NKTR: 61% vs. SKYE: 92%
Market capitalization -- NKTR: $1.09B vs. SKYE: $47.1M
NKTR [@Biotechnology] is valued at $1.09B. SKYE’s [@Biotechnology] market capitalization is $47.1M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NKTR’s FA Score shows that 0 FA rating(s) are green whileSKYE’s FA Score has 0 green FA rating(s).

  • NKTR’s FA Score: 0 green, 5 red.
  • SKYE’s FA Score: 0 green, 5 red.
According to our system of comparison, both NKTR and SKYE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NKTR’s TA Score shows that 4 TA indicator(s) are bullish while SKYE’s TA Score has 5 bullish TA indicator(s).

  • NKTR’s TA Score: 4 bullish, 3 bearish.
  • SKYE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NKTR is a better buy in the short-term than SKYE.

Price Growth

NKTR (@Biotechnology) experienced а -1.62% price change this week, while SKYE (@Biotechnology) price change was -8.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.44%. For the same industry, the average monthly price growth was +17.42%, and the average quarterly price growth was +81.94%.

Industries' Descriptions

@Biotechnology (+0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NKTR($1.09B) has a higher market cap than SKYE($47.1M). NKTR YTD gains are higher at: 309.032 vs. SKYE (-46.290). SKYE has higher annual earnings (EBITDA): -41.68M vs. NKTR (-87.3M). NKTR has more cash in the bank: 176M vs. SKYE (48.6M). SKYE has less debt than NKTR: SKYE (368K) vs NKTR (96.2M). NKTR has higher revenues than SKYE: NKTR (74.9M) vs SKYE (0).
NKTRSKYENKTR / SKYE
Capitalization1.09B47.1M2,304%
EBITDA-87.3M-41.68M209%
Gain YTD309.032-46.290-668%
P/E RatioN/A3.57-
Revenue74.9M0-
Total Cash176M48.6M362%
Total Debt96.2M368K26,141%
FUNDAMENTALS RATINGS
NKTR vs SKYE: Fundamental Ratings
NKTR
SKYE
OUTLOOK RATING
1..100
783
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
37
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3497
P/E GROWTH RATING
1..100
8398
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SKYE's Valuation (37) in the null industry is somewhat better than the same rating for NKTR (77) in the Biotechnology industry. This means that SKYE’s stock grew somewhat faster than NKTR’s over the last 12 months.

SKYE's Profit vs Risk Rating (100) in the null industry is in the same range as NKTR (100) in the Biotechnology industry. This means that SKYE’s stock grew similarly to NKTR’s over the last 12 months.

SKYE's SMR Rating (98) in the null industry is in the same range as NKTR (100) in the Biotechnology industry. This means that SKYE’s stock grew similarly to NKTR’s over the last 12 months.

NKTR's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for SKYE (97) in the null industry. This means that NKTR’s stock grew somewhat faster than SKYE’s over the last 12 months.

NKTR's P/E Growth Rating (83) in the Biotechnology industry is in the same range as SKYE (98) in the null industry. This means that NKTR’s stock grew similarly to SKYE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NKTRSKYE
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 14 days ago
78%
Bullish Trend 14 days ago
87%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
83%
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
NKTR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BIIEX27.090.09
+0.33%
Brandes International Equity I
CSRIX48.12N/A
N/A
Cohen & Steers Instl Realty Shares
MRRGX32.97N/A
N/A
Meridian Growth Institutional
SEEFX22.48N/A
N/A
Saturna Sustainable Equity
BRAGX110.19N/A
N/A
Bridgeway Aggressive Investors 1

NKTR and

Correlation & Price change

A.I.dvisor indicates that over the last year, NKTR has been loosely correlated with SLS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTR jumps, then SLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKTR
1D Price
Change %
NKTR100%
-0.59%
SLS - NKTR
42%
Loosely correlated
+2.50%
AMLX - NKTR
37%
Loosely correlated
+0.57%
EYPT - NKTR
36%
Loosely correlated
-1.35%
DNTH - NKTR
35%
Loosely correlated
+3.05%
RXRX - NKTR
35%
Loosely correlated
+6.51%
More

SKYE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with JANX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then JANX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKYE
1D Price
Change %
SKYE100%
+1.00%
JANX - SKYE
40%
Loosely correlated
-2.09%
VKTX - SKYE
34%
Loosely correlated
-2.54%
ABOS - SKYE
30%
Poorly correlated
+9.67%
RCKT - SKYE
30%
Poorly correlated
+23.05%
NKTR - SKYE
29%
Poorly correlated
-0.59%
More